S405
Clinical - Gynaecological
ESTRO 2026
personalized dose-constraint modeling are warranted to optimize patient selection and ensure treatment safety. References: 1. Mateusz Bilski, Paulina Marcyniuk, Monika Bilska, Pawel Cisek. Reirradiation Of Gynecological Recurrences With HDR Brachytherapy/Interventional Radiotherapy (I-RT) - A Single Institution Analysis, International Journal of Gynecological Cancer,Volume 35, Issue 2, Supplement 1,2025,100707,ISSN 1048- 891X, https://doi.org/10.1016/j.ijgc.2024.1007 07. Keywords: Reirradiation, Gynecologic cancer, Brachytherapy Oligometastatic Ovarian Cancer: Why the Radiation Oncologist Should Be Involved Sooner—Outcomes Stratified by ESTRO- EORTC Criteria Donato Pezzulla 1 , Maura Campitelli 2 , Savino Cilla 3 , Mara Fanelli 4 , Francesca Tortoreto 5 , Stefano Durante 6 , Andrei Fodor 7 , Giuseppe Roberto D'agostino 8 , Francesca Titone 9 , Lucia Giaccherini 10 , Lorena Draghini 11 , Edy Ippolito 12 , Francesca De Felice 13 , Antonietta Augurio 14 , Donatella Russo 15 , Marinella Tamburo 16 , Vittoria Balcet 17 , Simona Lucci 2 , Filippo Quattrocchi 2 , Giuseppe Vizzielli 18,19 , Francesco Deodato 1,20 , Gabriella Macchia 1 1 Radiation Oncology Unit, Responsible Research Hospital, Campobasso, Italy. 2 Dipartimento di Diagnostica per Immagini e Radioterapia Oncologica, Fondazione Poster Discussion 688 Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. 3 Medical Physics unit, Responsible Research Hospital, Campobasso, Italy. 4 Research Laboratories, Responsible Research Hospital, Campobasso, Italy. 5 UOC di Radioterapia Fatebenefratelli Isola Tiberina, Gemelli Isola, Rome, Italy. 6 Division of Radiation Oncology, European Institute of Oncology, IEO, IRCCS, Milan, Italy. 7 Department of Radiation Oncology, IRCCS
San Raffaele Scientific Institute, Milan, Italy. 8 Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Milan, Italy. 9 Radiation Oncology Unit, Department of Oncology, “Santa Maria della Misericordia” University Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy. 10 Radiation Oncology, Azienda USL – IRCCS di Reggio Emilia, Reggio Emilia, Italy. 11 Radiation Oncology Center, S Maria Hospital, Terni, Italy. 12 Operative Research Unit of Radiation Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy. 13 Radiation Oncology, AOU Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Rome, Italy. 14 Department of Radiation Oncology, SS Annunziata Hospita, Chieti, Italy. 15 Radiotherapy Unit, Vito Fazzi” Hospital, Lecce, Italy. 16 UOC di Radioterapia, Azienda Ospedaliera “Cannizzaro”, Catania, Italy. 17 UOC di Radioterapia, Nuovo Ospedale degli Infermi, Biella, Italy. 18 Clinic of Obstetrics and Gynecology, "Santa Maria della Misericordia" University Hospital Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy. 19 Department of Medicine (DMED), University of Udine, Udine, Italy. 20 Istituto di radiologia, Università Cattolica del Sacro Cuore, Rome, Italy
Purpose/Objective: In this post-hoc analysis of the phase II MITO RT3/RAD trial, ovarian cancer patients with oligometastatic disease (OMD) treated with
SBRT were reclassified using the ESTRO/EORTC criteria to assess the prognostic value of this framework. Material/Methods: Analysis employed the 9-category
ESTRO/EORTC OMD classification (de novo synchronous/metachronous, repeat, induced,
oligorecurrence, oligoprogression, oligopersistence, oligopersistent, and oligoprogressed). These were then consolidated into three main groups:
Made with FlippingBook - Share PDF online